Adjuvants and vector systems for allergy vaccines.
Immunol Allergy Clin North Am
; 31(2): 407-19, xii, 2011 May.
Article
em En
| MEDLINE
| ID: mdl-21530828
ABSTRACT
Allergen-specific immunotherapy represents a curative treatment of type I allergies. Subcutaneous immunotherapy is conducted with allergens adsorbed on aluminum hydroxide or calcium phosphate particles, whereas sublingual immunotherapy relies on high doses of soluble allergen without any immunopotentiator. There is a potential benefit of adjuvants enhancing regulatory and Th1 CD4+T cell responses during specific immunotherapy. Molecules affecting dendritic cells favor the induction of T regulatory cell and Th1 responses and represent valid candidate adjuvants for allergy vaccines. Furthermore, the interest in viruslike particles and mucoadhesive particulate vector systems, which may better address the allergen(s) to tolerogenic antigen-presenting cells, is documented.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Alérgenos
/
Vacinas
/
Adjuvantes Imunológicos
/
Dessensibilização Imunológica
/
Hipersensibilidade
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article